4th CML-CAB: Munich, Germany, 18-19 November 2017

On 18-19 November 2017, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted its fourth meeting to discuss issues of major concern to the CML community. The meeting was made up of 2 sessions: Novartis, Takeda/Incyte.

The following topics were discussed during the session with Incyte & Takeda, 18th November 2017, 13:00-17:00:

• Clinical Update on Ponatinib
• Discussion of The Lifecycle Plan for Ponatinib
• Access Issues
• Involvement of the CML Community in Research &
• Development (R&D)
• Dialogue and Next Steps

The following topics were discussed during the session with Novartis, 19th November 2017, 08:00-16:00:

• Clinical Development of ABL001 and Nilotinib
• Collaboration Between Novartis and CML Community in CML
• Drug Development
• Therapy-Free Remission
• Follow-up Actions and Next Steps